Providence Health & Services

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1859-01-01

Employees: 10K

Market Cap: -

Website: http://www.providence.org

Clinical Trials

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer
Melanoma
Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: GR-MD-02
Drug: Pembrolizumab

First Posted Date: 2015-10-14

Last Posted Date: 2023-06-05

Lead Sponsor: Providence Health & Services

Target Recruit Count: 36

Registration Number: NCT02575404

Locations: 🇺🇸
Providence Cancer Center, Portland, Oregon, United States

The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer

Phase 1

Terminated

Conditions: Esophagitis

Interventions: Dietary Supplement: Whole Food Intervention

First Posted Date: 2015-10-14

Last Posted Date: 2015-10-14

Lead Sponsor: Providence Health & Services

Target Recruit Count: 7

Registration Number: NCT02575391

Locations: 🇺🇸
The Oregon Clinic, Providence Portland Cancer Center, Portland, Oregon, United States
🇺🇸
Integrative Medicine Program, Providence St. Vincent Medical Center, Portland, Oregon, United States

The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer

Phase 1

Terminated

Conditions: Mucositis

Interventions: Dietary Supplement: Whole Food Intervention

First Posted Date: 2015-10-14

Last Posted Date: 2015-10-14

Lead Sponsor: Providence Health & Services

Target Recruit Count: 10

Registration Number: NCT02575313

Locations: 🇺🇸
The Oregon Clinic, Providence Portland Cancer Center, Portland, Oregon, United States
🇺🇸
Integrative Medicine Program, Providence St. Vincent Medical Center, Portland, Oregon, United States

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

Phase 1

Terminated

Conditions: Colorectal Neoplasms

Interventions: Drug: MEDI6469

First Posted Date: 2015-09-24

Last Posted Date: 2022-02-14

Lead Sponsor: Providence Health & Services

Target Recruit Count: 4

Registration Number: NCT02559024

Locations: 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: MK-3475
Drug: Gemcitabine

First Posted Date: 2015-04-21

Last Posted Date: 2023-10-26

Lead Sponsor: Providence Health & Services

Target Recruit Count: 16

Registration Number: NCT02422381

Locations: 🇺🇸
Providence Oncology & Hematology Care Clinic - Westside, Portland, Oregon, United States
🇺🇸
Providence Oncology & Hematology Care Clinic - Eastside, Portland, Oregon, United States

ACTH for Fatigue in Multiple Sclerosis Patients

Phase 3

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: ACTH
Drug: Placebo

First Posted Date: 2014-12-12

Last Posted Date: 2019-09-09

Lead Sponsor: Providence Health & Services

Target Recruit Count: 8

Registration Number: NCT02315872

Locations: 🇺🇸
North Central Neurology Associates, PC, Cullman, Alabama, United States
🇺🇸
Providence Medical Group - Medford Neurology, Medford, Oregon, United States
🇺🇸
Swedish Medical Center, Seattle, Washington, United States

and more 2 locations

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Phase 2

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Biological: High Dose IL-2
Radiation: SBRT

First Posted Date: 2014-12-03

Last Posted Date: 2024-01-25

Lead Sponsor: Providence Health & Services

Target Recruit Count: 84

Registration Number: NCT02306954

Locations: 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States

Anti-OX40 Antibody in Head and Neck Cancer Patients

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Anti-OX40 antibody administration
Procedure: Surgical Resection

First Posted Date: 2014-10-24

Last Posted Date: 2024-02-07

Lead Sponsor: Providence Health & Services

Target Recruit Count: 17

Registration Number: NCT02274155

Locations: 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States

α-TEA in Advanced Cancer

Phase 1

Completed

Conditions: Metastatic Carcinoma
Metastatic Sarcoma
Metastatic Lymphoma

Interventions: Drug: 12 mg/kg α-TEA
Drug: 19.2 mg/kg α-TEA
Drug: 2.4 mg/kg α-TEA
Drug: 4.8 mg/kg α-TEA
Drug: 8.0 mg/kg α-TEA
Drug: 16.8 mg/kg α-TEA
Drug: 9.6 mg/kg α-TEA
Drug: 22.3 mg/kg α-TEA
Drug: 26.8 mg/kg α-TEA

First Posted Date: 2014-07-16

Last Posted Date: 2018-08-17

Lead Sponsor: Providence Health & Services

Target Recruit Count: 17

Registration Number: NCT02192346

Locations: 🇺🇸
Providence Oncology & Hematoloty Care Clinic- Newberg, Newberg, Oregon, United States
🇺🇸
Providence Oncology & Hematology Care Clinic- Willamette Falls, Oregon City, Oregon, United States
🇺🇸
Providence Oncology & Hematology Care Clinic- Eastside, Portland, Oregon, United States

and more 2 locations

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Metastatic Melanoma

Interventions: Biological: 8 mg/kg GR-MD-02
Biological: 4 mg/kg GR-MD-02
Biological: 1 mg/kg GR-MD-02
Biological: 2 mg/kg GR-MD-02
Biological: Ipilimumab

First Posted Date: 2014-04-17

Last Posted Date: 2019-03-21

Lead Sponsor: Providence Health & Services

Target Recruit Count: 8

Registration Number: NCT02117362

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy